RT Journal Article
T1 Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers.
A1 León-González, Antonio J
A1 Jiménez-Vacas, Juan M
A1 Fuentes-Fayos, Antonio C
A1 Sarmento-Cabral, Andre
A1 Herrera-Martínez, Aura D
A1 Gahete, Manuel D
A1 Luque, Raúl M
K1 Cancer
K1 insulin
K1 metabolic syndrome
K1 metformin
K1 statins
AB Metabolic syndrome is associated with chronic diseases, including type 2 diabetes, cardiovascular diseases, and cancer. This review summarizes the current evidence on the antitumor effects of some relevant drugs currently used to manage metabolic-related pathologies (i.e. insulin and its analogs, metformin, statins, etc.) in endocrine-related cancers including breast cancer, prostate cancer, pituitary cancer, ovarian cancer, and neuroendocrine neoplasms. Although current evidence does not provide a clear antitumor role of several of these drugs, metformin seems to be a promising chemopreventive and adjuvant agent in cancer management, modulating tumor cell metabolism and microenvironment, through both AMP-activated protein kinase-dependent and -independent mechanisms. Moreover, its combination with statins might represent a promising therapeutic strategy to tackle the progression of endocrine-related tumors. However, further studies are needed to endorse the clinical relevance of these drugs as adjuvants for cancer chemotherapy.
YR 2021
FD 2021-07-23
LK https://hdl.handle.net/10668/28264
UL https://hdl.handle.net/10668/28264
LA en
DS RISalud
RD Apr 4, 2025